Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination

BACKGROUND: An AS03-adjuvanted H5N1 influenza vaccine elicited broad and persistent immune responses with an acceptable safety profile up to 6 months following the first vaccination in children aged 3–9 years. METHODS: In this follow-up of the Phase II study, we report immunogenicity persistence and...

Descripción completa

Detalles Bibliográficos
Autores principales: Díez-Domingo, Javier, Baldó, José-María, Planelles-Catarino, Maria Victoria, Garcés-Sánchez, María, Ubeda, Isabel, Jubert–Rosich, Angels, Marès, Josep, Garcia-Corbeira, Pilar, Moris, Philippe, Teko, Maurice, Vanden Abeele, Carline, Gillard, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353319/
https://www.ncbi.nlm.nih.gov/pubmed/25652873
http://dx.doi.org/10.1111/irv.12295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353319/
https://www.ncbi.nlm.nih.gov/pubmed/25652873
http://dx.doi.org/10.1111/irv.12295

Ejemplares similares